The past decade has seen increased application of 18-fl urodeoxyglucose positron emission tomography ( 18 FDG-PET) imaging to help diagnose and monitor disease, particularly in oncology, vasculitis and atherosclerosis. Disordered glycolytic metabolism and infi ltration of plexiform lesions by infl ammatory cells has been described in idiopathic pulmonary arterial hypertension (IPAH). We hypothesized that increased 18 FDG uptake may be present in the lungs, large pulmonary arteries and right ventricle of patients with pulmonary hypertension, and that this uptake would be related to markers of immune activation. We imaged the thorax of 14 patients with pulmonary hypertension (idiopathic and chronic thromboembolic) and six controls by 18 FDG-PET/computed tomography (CT) and measured uptake in the lung parenchyma, large pulmonary arteries and right ventricle.
INTRODUCTION
Idiopathic pulmonary arterial hypertension (IPAH) is a condition associated with endothelial dysfunction, small pulmonary artery smooth muscle cell and ibroblast proliferation, and in situ thrombosis. These changes result in an elevated pulmonary vascular resistance (PVR), which may progress to failure of the right ventricle and death. A large contribution to the PVR comes from small precapillary "resistance" arteries. [1] The etiology of IPAH
18
FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study is unclear, with abnormalities found in many cellular pathways [2] as well as heritable cases being caused by mutations in the bone morphogenetic protein receptor type II (BMPR-II) gene. [3] Pulmonary hypertension may be associated with other conditions, such as chronic thromboemboli in the pulmonary arteries (chronic thromboembolic pulmonary hypertension (CTEPH)). [4] There is mounting evidence that immune dysregulation and possibly in lammation play a role in IPAH. Patients with IPAH have elevated serum levels of the proin lammatory cytokines interleukin (IL)-1 and IL-6 [5] (5) and C-reactive protein [6] in comparison with healthy controls. Recently, elevated levels of ILs 6, 8, 10 and 12p70 have been shown to predict survival in patients with pulmonary arterial hypertension. [7] The source of production of these cytokines in pulmonary hypertension is largely unknown, but may be the lungs. [8] In iltrates of T-cells, B-cells and macrophages are seen in the plexiform lesions often found in IPAH. [9] The role of immune dysregulation in CTEPH is less clear. Raised serum levels of the proin lammatory cytokines IL-10 and tumor necrosis factor alfa (TNFα) have been described in CTEPH. [10] The past decade has seen the development of imaging techniques able to detect and track changes in vascular in lammation. [11, 12] There has been particular interest in the use of 18-lurodeoxyglucose positron emission tomography ( 18 FDG-PET), an imaging technique that is sensitive to cellular processes that metabolize glucose. 18 FDG is taken up into cells via glucose transporter proteins, and phosphorylated to 18 FDG-6-phosphate, which cannot be metabolized further along the glycolytic pathway and accumulates within cells in proportion to their glucose uptake (and hence metabolic activity). While commonly used in oncology to identify primary and metastatic tumor cells, several other cell types may also demonstrate high levels of 18 FDG accumulation, including activated leucocytes, [13] lymphocytes [14] and ibroblasts. [15] Increased 18 FDG uptake has been demonstrated in animal models of in lammation [16] as well as a range of human in lammatory conditions including abscesses, [17] tuberculosis, [18] sarcoidosis [19] and large vessel vasculitis.
[20] 18
FDG uptake in atherosclerosis of the aorta and carotid and vertebral arteries at PET imaging correlates with the presence of vascular symptoms, [21] risk factor load [22] and in lammatory biomarker levels. [23] Such imaging might have a role in monitoring the response of atherosclerosis to therapy. [24] Several human cancer cell lines have high mitochondrial membrane potentials and low expression of the Kv1.5 potassium channel, which may lead to an apoptosisresistant phenotype and a switch to glycolytic metabolism; [25] these energy-handling abnormalities have also been described in IPAH. [26, 27] Increased glycolytic metabolism is present in endothelial cells derived from IPAH-transplant explants; [28] this study also described higher 18 FDG lung uptake on PET scan than normal control patients, with the uptake ascribed to increased vascular endothelial glycolytic activity. 18 FDG-PET imaging of the heart in PAH shows excessive 18 FDG uptake within the wall of the pressure-overloaded right ventricle, with the degree of uptake correlating with pulmonary hemodynamics. [29] Given the possible pathological role of in lammation in idiopathic PAH and CTEPH, the presence of deranged endothelial cell bioenergetics and the recent development of techniques allowing the imaging of vascular in lammation, we hypothesized that increased 18 FDG uptake in the large "conduit" pulmonary arteries, lung parenchyma and right ventricle would be present in subjects with pulmonary hypertension compared with controls. We also determined whether 18 FDG uptake correlated with systemic in lammation as evaluated by levels of relevant in lammatory cytokines.
MATERIALS AND METHODS

Study population
Outpatients attending our national pulmonary hypertension referral service at Papworth Hospital, Cambridge, UK, with a diagnosis of IPAH or CTEPH with a distal distribution of disease were recruited. All patients met recognized diagnostic criteria. [30] Exclusion criteria were a diagnosis of connective tissue, diabetes, intercurrent infection or in lammatory lung disease (e.g., bronchiectasis, emphysema). All patients gave written informed consent and the study was approved by the Cambridgeshire Regional Ethics Committee.
The comparator group was comprised of a group of healthy ex-smokers (median smoking history of 10 pack years) without chronic obstructive pulmonary disease or pulmonary hypertension from a recent imaging study. [31] Sample sizes were based on previous vascular PET/ computed tomography (CT) studies and powered to show differences in uptake between vascular beds. [31, 32] 
18
FDG-PET/CT
Imaging was performed using a PET/CT system (GE Discovery 690). All subjects fasted for 6 h before imaging; 222-239 MBq (average 232 MBq) of 18 FDG was injected intravenously after which subjects rested in a quiet room. PET/CT acquisition began 85-96 min after injection. PET acquisition was for 20 min over the mediastinum to include the pulmonary arteries and right ventricle. Low-dose CT of the thorax was performed immediately prior to the PET to allow anatomic colocalization and attenuation correction of PET data. No CT contrast was administered. Attenuation-corrected PET images were iteratively reconstructed using "Time of Flight" information. [33] PET/CT image analysis was performed using Osirix version 3.7.1 (Osirix Imaging Software, Geneva, Switzerland). The ascending aorta, main pulmonary arteries and pulmonary trunk, lung parenchyma and right and left ventricles were analyzed, described in detail below. Regions of interest were placed by one reader blinded to the diagnosis (GH) and reviewed independently by two readers prior to the inal analysis.
Mean and maximum body weight-corrected standardized uptake values (SUV) were calculated from the pixel activity within each region of interest (ROI). Where appropriate, SUVs were normalized to blood 18 FDG activity by dividing the average SUV by the uptake of superior vena cava (SVC) blood to give a blood-corrected SUV, known as a target-to-background ratio (TBR), a validated technique for vascular PET imaging. [34] Ascending aorta
The ascending aorta was identi ied from anatomic landmarks on CT. As previously described, [31] the maximum SUV was measured from a circular ROI placed around the lumen on each transaxial slice (approximately 10 per subject), from which TBR was derived.
Large pulmonary arteries
We were unable to ind published methods for determining 18 FDG uptake in the pulmonary arteries on PET/CT. We therefore adapted methods validated in atherosclerosis imaging studies. [23, 24] The pulmonary trunk and right and left main pulmonary arteries were included in the analysis and identi ied from anatomic CT landmarks. The region bordered inferiorly by the right ventricular out low tract to the superior limit of the pulmonary trunk was included, and ROIs drawn around the pulmonary trunk to the distal limit of the main pulmonary arteries on each transaxial slice. An average SUV max and TBR were derived.
Lung parenchyma
ROIs of radius 1 cm were drawn in peripheral lung locations, away from obvious pulmonary vessels in the anterior, middle and posterior sections of each lung (to minimize any effects of gravitational pooling of the blood pool and lung heterogeneity) on a transaxial slice taken at the level of the carina. ROI placement was validated by a thoracic radiologist blinded to the patient group (NS). SUV max was measured from which the TBR was derived as per published methods. [35, 36] 
Right ventricle
As previously described, [29] we placed a number ( ive to 14) of circular ROIs on each of the RV and LV free walls of a transaxial image to obtain an averaged mean SUV. We compared 18 FDG uptake in the right and left ventricles using the ratio method of Kluge. [37] Biomarkers Immediately prior to PET/CT imaging, venous blood was drawn for high-sensitivity C-reactive protein (hsCRP), N-Terminal Probrain natriuteric peptide (NT-ProBNP) and in lammatory cytokine analyses. NT-ProBNP was analyzed using a Siemens Dimension Clinical chemistry system and hsCRP using a Dade Behring immunonephelometry assay. Blood for in lammatory cytokines was centrifuged for 10 min at 3,000 revolutions per minute, and the serum supernatant removed and stored at -85°C for analysis.
Serum levels of in lammatory cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, interferon [IFN]-γ and TNFα) were measured using a high-sensitivity cytokine multiplex assay and a multiplex analyzer following the manufacturer's protocols.
Statistics
One-way ANOVA was used for comparisons among the three groups. When a P-value under 0.05 was found, Tukey's post test comparison was performed between individual groups. For comparison between two groups, an unpaired Student's t test was used if the data were normally distributed; otherwise, the Mann-Whitney test was used. Associations between variables were tested using Pearson's correlation for normally distributed values and Spearman's rank correlation for nonnormally distributed data. The intraclass correlation coef icient (ICC) was used to ascertain intrareader reproducibility. Analysis was performed using GraphPad Prism software (Version 5.02). Statistical signi icance was set at the 5% level.
Intrareader reproducibility
Six scans were reread after 3 months to estimate the intrareader variability. There was no signi icant difference between results, and the TBR values were highly reproducible (intraclass correlation coef icient for aorta: 0.95, large pulmonary arteries: 0.99).
RESULTS
Demographic, imaging and biochemical data for all three groups are summarized in (Table 1) . Eight IPAH patients, six CTEPH patients and six comparator subjects were enrolled: Seven/eight idiopathic PAH and ive/six distal CTEPH patients were receiving PAH-targeted therapy (phosphodiesterase-5 inhibitor, endothelin antagonist or prostanoid). There was no difference in the body mass index or 18 FDG circulation time among the three groups. No IPAH patients carried a BMPR2 mutation. Values given as mean±SD; *P<0.05 compared with the comparator group; † P<0.01 compared with the comparator group; IPAH: idiopathic pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; PET/CT: positron emission tomography/ computed tomography; TBR: target-to-background ratio; SUV: standardized uptake values PET and fused PET/CT images of the right ventricle and the pulmonary trunk of an IPAH subject are shown in (Fig. 1) .
Large vessel uptake
There were no signi icant differences in 18 FDG uptake (expressed as TBR) in the ascending aorta (Fig. 2) or in the main pulmonary arteries between the IPAH, CTEPH and comparator groups (Fig. 3) .
Lung parenchymal uptake
Idiopathic PAH patients had a signi icantly higher lung parenchymal TBR max than the comparator group (P=0.034). There w ere no overall differences between the CTEPH group and either the comparator or the idiopathic PAH group (Fig. 4) .
LV uptake, RV uptake and RV/LV ratio
There was no difference in LV uptake among the three groups. Both RV uptake (Fig. 5) and the RV/LV ratio were signi icantly higher in idiopathic PAH patients than in the comparator group (P=0.007 for RV, P=0.017 for RV/LV). There were no differences between the CTEPH group and the other two groups. 
SVC venous blood uptake
There was no signi icant difference between venous blood uptake among the three groups.
Correlation between uptake in RV, pulmonary arteries and lung parenchyma
The RV uptake did not correlate with lung parenchymal uptake or pulmonary artery uptake in any group. Pulmonary artery uptake correlated with lung parenchymal uptake for both the IPAH group (r=0.81, P=0.0153) and the combined IPAH and CTEPH groups (r=0.71, P=0.0039) and also in the comparator group(r=0.91, P=0.012).
Correlation with inflammatory cytokines and NT-ProBNP
Cytokine measurements were not available for the comparator group. The levels of hsCRP, cytokines or NT-ProBNP did not differ signi icantly between the IPAH and the CTEPH groups. There was an association (r=0.55, P=0.04) between NT-ProBNP and RV uptake for the combined IPAH and CTEPH groups. NT-ProBNP levels did not correlate with lung parenchymal or large vessel (aorta or pulmonary) uptake in either group. There was no correlation between large pulmonary artery TBR, lung parenchymal TBR or RV uptake and hsCRP or any of the in lammatory cytokines in either group.
DISCUSSION
To our knowledge, this is the irst study to attempt to measure endothelial metabolism, in lammatory cell activity or vascular remodeling using the surrogate of 18FDG uptake in the pulmonary arteries in pulmonary hypertension. In this pilot prospective imaging study, we demonstrated that lung 18 FDG uptake, expressed as TBR, is higher in patients with idiopathic PAH than the comparator or CTEPH group. RV uptake was also higher in our IPAH patients than comparators. Correlations between lung parenchymal uptake and pulmonary artery uptake were present. There was no difference in the uptake in the large pulmonary arteries or aorta among the three groups. The absence of signi icantly increased uptake in the large pulmonary arteries suggests that these processes are con ined to the distal vessels in this disease.
Our results are concordant with previously published studies. Increased lung parenchymal 18 FDG uptake in IPAH was reported in a smaller study (n=4). [28] A positive correlation between adverse pulmonary hemodynamics and RV 18 FDG uptake has been described. [29] The RV uptake in our pulmonary hypertension group (IPAH and CTEPH) correlated with NT-ProBNP. We did not examine correlations between right heart catheter or echocardiographic indices and 18 FDG uptake as there was a time interval of a few months between the hemodynamic investigations and the PET/CT scan for most patients. We found no correlation between 18 FDG uptake in any region and in lammatory cytokine or hsCRP levels. As RV uptake in IPAH correlates with hemodynamics, [29] and little or no correlation exists between in lammatory cytokines or hsCRP and hemodynamics, [5, 6, 7] a correlation between RV uptake and in lammatory cytokines may not be expected.
The reasons for the increased lung parenchymal TBR in IPAH are unclear. Increased glycolytic metabolism of pulmonary artery endothelial cells has been proposed. [28] Rapidly dividing cells, including leucocytes [13] and ibroblasts, [15] have also increased glucose uptake and, therefore, lung TBR may be a surrogate marker of pulmonary vascular remodeling. In lammatory cells in plexiform lesions may also represent a source of 18 FDG uptake. The correlation between lung parenchymal TBR and pulmonary artery TBR may be due to the same underlying changes in glycolytic metabolism, or those patients with a more severe small resistance pulmonary artery vasculopathy having more in lammatory or ibroblast cells present in the larger conduit pulmonary arteries. The correlation was also seen in the comparator group, although numbers were small.
The absence of signi icantly increased uptake in the large pulmonary arteries is also of interest. While some earlier reports suggest the presence of atherosclerotic-like lesions in the pulmonary arteries, [38] these reports predate the modern treatment era of pulmonary hypertension. The majority of our IPAH patients were clinically stable patients under long-term follow-up at our center. Therefore, treatment-naïve incident patients or unstable patients were underrepresented. Markers of in lammation (hsCRP and in lammatory cytokines) in our IPAH pulmonary hypertension cohort were lower than those in the published literature. Quarck et al. [6] described a mean hsCRP of 4.4 mg/L (con idence interval 3.5-5.4) in treatment-naïve idiopathic PAH patients, which was signi icantly higher than their control group who had a mean hsCRP of 2.3 mg/L (con idence interval 1.9-2.7), whereas our idiopathic PAH cohort had a mean hsCRP of only 1.86. Our cytokine values were also lower than that of the study of Soon et al. [7] This data suggest that our pulmonary hypertensive patients had well-controlled stable disease. Even though no differences in large pulmonary artery uptake were found between the IPAH group and the comparator group, the IPAH group had a few "outliers" that could be representative of a different IPAH phenotype. The two patients with the highest large pulmonary artery TBR values included a 33-yearold male with rapidly progressive IPAH listed for lung transplantation and a 45-year-old female with relatively stable disease. They both also had hsCRP values above the mean for the IPAH group.
There were some limitations to this study. The number of patients was small, although we did show signi icant differences between the groups. Lack of simultaneous hemodynamic measurements precluded direct correlation with 18 FDG uptake, although NT-ProBNP levels were measured. Our imaging protocol was designed for maximizing uptake in vascular structures, not the right ventricle; therefore, caution is advised in the interpretation of the RV uptake results. A dedicated PET/CT study of the right ventricle would require ECG gating and clamping of glucose levels.
Similar to 18 FDG PET, there are other vascular imaging techniques that may have a role in answering the questions raised in this study. Animal models suggest that macrophage-targeted CT contrast agents may measure in lammation in atherosclerosis. [39] Ultra-small superparamagnetic iron oxide particles accumulate in macrophages in carotid artery plaques, which then can be quanti ied using high-resolution magnetic resonance imaging. [40] It would be of interest to apply these novel methods of disease assessment in pulmonary arterial hypertension, particularly for assessing the impact of targeted therapy on treatment-naïve patients and identi ication of novel drugs at early stages of development. Further studies may also clarify the signi icance of RV 18 FDG uptake in pulmonary hypertension of different etiologies with measurement of contemporaneous hemodynamics.
CONCLUSION
In this pilot study, we demonstrated increased 18 FDG uptake in the lungs of patients with IPAH, and higher RV uptake in pulmonary hypertensive subjects compared with controls. Increased lung uptake may be due to changes in glycolytic metabolism in endothelial cells in IPAH or an increased amount of cells involved in in lammation. Further imaging studies in treatment-naïve patients, to measure the impact of targeted therapies on the lung, 18 FDG signal and dedicated imaging of the right ventricle uptake may provide validation of this approach.
